Puremend gradient small.png
Dr. Mitchell Sanders

Dr. Mitch Sanders is a serial entrepreneur & angel investor with 30+ years preclinical animal models and clinical product development in advanced wound care. Mitch has secured an aggregate of $45M in development funding, and grants and has worked on bringing over 20 products through product development. Major clients include JNJ (Ethicon, Consumer & Vistakon), Unilever, Reckitt Benckiser, Systagenix, Stryker Orthopedics, and AstraZeneca. In October 2014, Mitch joined Alira Health part-time to help expand their newly formed and rapidly growing Global Medical Affairs Division. In April of 2015, he was promoted to Managing Director of Drug and Device Discovery Lab (3DL) now rebranded as the Product Development Lab. In February of 2018, he was promoted to the Chief Scientific Officer of Alira Health, Board Member, & Founder of two Alira Health Ventures SPVs: Firefly Innovations LLC (www.PureMend.com) and WoundForce LLC (woundforce.com). In 2019, Mitch is head of the Wound Healing Society (WHS) Communications Committee and serves on the Program and Industrial Relations Committee.

Mitch is an expert in clinical and translational research and is a reviewer for the Wound Healing Society (WHS), Wounds International, Tissue Engineering, CIMIT, MassVentures, MIT, WPI, Tech Sandbox, Piranha Pond, SBANE and the WPI Venture Forum. Mitch has a BA in Biology with a Minor in Latin Language and Literature at Boston University. He has an MS and PhD from WPI in Molecular Biology and Biomedical Sciences with two Postdocs at the Whitehead Institute/MIT in Biochemistry and Pathogen Genetics. Mitch is also an AALAS certified Laboratory Animal Technician and has 30+ year of expertise in performing preclinical wound healing and surgical models at ECI Biotech, Boston University, Alira Health and UMASS Medical School. 

Advisory Board

Elite though leaders in advanced wound care providing commercial, clinical and scientific expertise and bringing a strong track record of successful commercial launches.

BW cropped.png
Barry Wolfenson
Dr. Cassandra Quave, PhD
Dr. Tom Serena

Barry Wolfenson is a senior executive with over 15 years of experience in the advanced wound care industry. He previously served as CEO of Sano, LLC, a medical diagnostics company focused on the early detection of inflammation in various disease states. Prior to that, he served as President of the Advanced Wound Care division within Derma Sciences, after having led the creation of that division. While at Derma Sciences he ran one of the largest drug development programs in the field of advanced wound care, was responsible for all business development activities of the division, and managed the sales, marketing, and clinical departments. He also served in a variety of roles at Bristol-Myers Squibb, and was a consultant at Andersen Consulting. Barry received an MBA at the University of Michigan, and a BS in Economics with a Pre-Med Concentration at Franklin & Marshall College.

Dr. Cassandra Quave is Curator of the Emory University Herbarium and Assistant Professor of Dermatology and Human Health at Emory University, where she leads antibiotic drug discovery research initiatives and teaches. Trained as a medical ethnobotanist, her research is focused on the documentation and biochemical analysis of botanical remedies used in the traditional treatment of infectious and inflammatory skin disease. To date, she has authored more than 60 publications, 2 edited books and 3 patents. Dr. Quave is the co-founder and CEO/CSO of PhytoTEK LLC, a drug discovery company dedicated to developing solutions from botanicals for the treatment of recalcitrant antibiotic resistant infections. Her work has been profiled in the New York Times Magazine, BBC Focus and National Geographic Channel, and featured on NPR, and several major news outlets including the Washington Post, The Telegraph, CBS News, and NBC News. 

Dr. Thomas E. Serena MD is the Founder and Medical Director of SerenaGroup, and has opened and currently operates wound care centers around the world. Tom has been the lead investigator in 100+ clinical trials across many verticals of wound care, and holds numerous patents on wound care devices and dressings. Tom is internationally recognized as a leader in the field of wound healing, as he has written 200+ published papers and has given 1000+ invited lectures around the world. He has served on multiple boards in the wound care/healing space and is now the president-elect of the Association for the Advancement of Wound Care (AAWC) Tom is a graduate of The College of William & Mary and Penn State Medical School, and completed his residency in surgery at The Milton S. Hershey Medical Center with an additional year of training at Southern Illinois University. 

Dr. Greg Schultz
Biofilm Research

Gregory Schultz, PhD, is Professor of Obstetrics and Gynecology and Director of the Institute for Wound Research at the University of Florida.  Dr Schultz graduated with BS and PhD degrees in Biochemistry from Oklahoma State University then completed Postdoctoral research in Cell Biology at Yale University. Dr Schultz’s research focuses primarily on defining the molecular and cellular regulators of normal wound healing and developing therapies that reduce excessive scar formation (fibrosis). Another major area of his research focuses on detecting and killing bacterial biofilms that stimulate chronic inflammation and proteases that impair healing in chronic wounds and developing advanced therapies that promote healing. Dr. Schultz has co-authored 400 scientific publications that have been cited over 17,200 times, has received $38 million in grant support as PI or Co-investigator, is an inventor on 32 patents, and is a cofounder of two biotech companies in the areas of antimicrobial coatings and antiscarring drugs.  He served as President of the Wound Healing Society from 1999 to 2001 and as a member of the National Pressure Ulcer Advisory Panel from 2007 to 2010.